Gelesis Holdings, Inc. (GLS) |
|
0.48 0.135 (39.29%)
|
12-02 16:01 |
|
Open: |
0.3658 |
Pre. Close: |
0.3446 |
|
High:
|
0.48 |
Low:
|
0.3283 |
|
Volume:
|
203,067 |
Market Cap:
|
35(M) |
|
|
|
Technical analysis |
as of: 2022-12-02 4:23:12 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 0.64 One year: 0.75 |
| Support: |
Support1: 0.35 Support2: 0.23 |
| Resistance: |
Resistance1: 0.55 Resistance2: 0.64 |
| Pivot: |
0.39 |
| Moving Average: |
MA(5): 0.37 MA(20): 0.36
MA(100): 0.96  MA(250): 3.32 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 41.5 %D(3): 40.5 |
| RSI: |
RSI(14): 47.5 |
| 52-week: |
High: 12.22 Low: 0.23 |
| Average Vol(K): |
3-Month: 154 (K) 10-Days: 115 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GLS ] has closed below upper band by 36.5%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.48 - 0.49 |
0.49 - 0.49 |
|
Low:
|
0.32 - 0.32 |
0.32 - 0.33 |
|
Close:
|
0.41 - 0.42 |
0.42 - 0.43 |
|
Company Description |
|
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts. |
Headline News |
Wed, 30 Nov 2022
2022 Mercedes-Benz GLB First Drive Review: Scaled-down GLS for GLC money? - Zee News
Wed, 30 Nov 2022
Mercedes GLB three-row SUV is your 'affordable' alternative to GLS - HT Auto
Tue, 29 Nov 2022
GLS-backed student team to develop in-air cargo drone charging system - Cargo Facts
Tue, 29 Nov 2022
Mansory Thinks the Maybach GLS Deserves a Bulbar and a New Photo Shoot, What Say You? - autoevolution
Mon, 28 Nov 2022
Late, Post-COVID Cardiac Dysfunction Linked to Preexisting CAD - Medscape
Mon, 28 Nov 2022
Suryakumar Yadav gives spa to his Mercedes Benz GLS SUV: SKY's car collection, net worth - DNA India
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
52.5 (%) |
|
% Held by Institutions
|
34.1 (%) |
|
Shares Short
|
867 (K) |
|
Shares Short P.Month
|
558 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-562 |
|
Return on Assets (ttm)
|
-56.6 |
|
Return on Equity (ttm)
|
-234.7 |
|
Qtrly Rev. Growth
|
312 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.21 |
|
EBITDA (p.s.)
|
-1.48 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-60 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
1.95 |
|
Price to Cash Flow
|
-0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
